Funds will support productization and clinical testing of Resonance Sonomanometry™ technology for calibration-free, noninvasive, continuous blood pressure monitoring. 

IRVINE, Calif., Feb. 18, 2025 /PRNewswire/ — Esperto Medical™, Inc. a healthtech startup specializing in critical care and remote patient monitoring, announces the closing of an oversubscribed Series A investment round co-led by Catalyst Health Ventures and Bold Capital Partners, with support from Wavemaker Three-sixty Health, Free Flow Ventures, Fund@Caltech and Maverick Ventures. 

The funds will support productization and clinical testing of Esperto’s new Resonance Sonomanometry™ (RSM) technology.  RSM uses sound waves at different frequencies to directly measure blood pressure within arteries, avoiding the variability of other approaches – and requires no calibration, making it easy to set up and use.  Details of the technique are published in PNAS Nexus.

Copyright © 2025 Cision US Inc.